In female rats, inhaled high-CBD whole-plant cannabis extract prevented morphine-induced place preference, blocked reinstatement, and reduced fentanyl self-administration, all without affecting lung tissue, cognition, or estrous cycle.
Addiction researchers, pain scientists, harm reduction advocates, opioid use disorder clinicians.
High-CBD vapor prevented morphine reward and reduced fentanyl self-administration in female rats
What the researchers found
High-CBD whole-plant extract (WPE) vapor prevented morphine-induced conditioned place preference and reinstatement. WPE reduced fentanyl self-administration in rats with and without neuropathic pain. WPE showed modest efficacy against cold allodynia in nerve-injured rats. Chronic exposure did not affect lung tissue, cognition, social behavior, or estrous cycle. WPE vapor had no reinforcing properties.
Why it matters
Most cannabis and opioid research has been done in male animals. This study fills a critical gap by showing that high-CBD cannabis vapor can reduce opioid reward and self-administration in females specifically, which matters because chronic pain is more prevalent in women.
The numbers in context
WPE prevented morphine conditioned place preference and reinstatement. Reduced fentanyl self-administration in both injured and non-injured rats. Modest cold allodynia reversal. No lung cytoarchitecture changes. No cognitive, social, or reproductive effects.
How the study worked
Comprehensive preclinical analysis in female rats including conditioned place preference, fentanyl self-administration, neuropathic pain models (spared nerve injury), cognitive and social behavior tests, lung histology, and estrous cycle monitoring.
What this study cannot tell us
Animal study in female rats only. Modest analgesic effect against neuropathic pain. Cannot directly extrapolate vapor doses to human vaping. Short-term exposure only. Single cannabis extract may not represent all products.
How to read the evidence
Comprehensive preclinical study with multiple behavioral paradigms, but limited to female rats.
When this study was published
Published in 2023.
The bigger picture
The combination of reducing opioid reward, having a robust safety profile, and lacking abuse potential makes high-CBD cannabis vapor an intriguing candidate for opioid use disorder research. The fact that it reduced fentanyl self-administration even in rats with neuropathic pain is particularly relevant to the opioid crisis.
Questions still open
- Would these opioid-sparing effects translate to human clinical trials?
- Would combining high-CBD vapor with standard opioid use disorder treatment improve outcomes?
Common questions
Can CBD reduce opioid addiction?
Is vaping CBD safe for the lungs?
Read the original research
High-CBD Cannabis Vapor Attenuates Opioid Reward and Partially Modulates Nociception in Female Rats.
Addiction neuroscience, 5
Citation
Rivera-Garcia, Maria T; Rose, Rizelle Mae; Wilson-Poe, Adrianne R. (2023). High-CBD Cannabis Vapor Attenuates Opioid Reward and Partially Modulates Nociception in Female Rats.. Addiction neuroscience, 5. https://doi.org/10.1016/j.addicn.2022.100050
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk